2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161646
    P-selectin antagonist 1 2099111-75-6 98%
    P-selectin antagonist 1 (Compound 11b) is an antagonist for pan-selectin (IC50 is 82 μM) and E-selectin (KD is 0.91 μM).
    P-selectin antagonist 1
  • HY-161660
    DS44470011 1192586-35-8 98%
    DS44470011 is a hypoxia-inducing factor prolyl hydroxylase (HIF-PHD) inhibitor. DS44470011 has oral activity. DS44470011 promotes cell release of erythropoietin (EPO). DS44470011 can be used in the research of renal anemia.
    DS44470011
  • HY-161663
    Phosphodiesterase-IN-2 3047610-96-5 98%
    Phosphodiesterase-IN-2 (Compound C7) is a selective, orally active inhibitor for phosphodiesterase 10A (PDE10A), with an IC50 of 11.9 nM. Phosphodiesterase-IN-2 improves the stability of liver microsomes, and lowers BBB permeability. Phosphodiesterase-IN-2 exhibits good pharmacokinetic characters, and attenuates isoprenaline (HY-108353)-induced cardiac hypertrophic in mouse models.
    Phosphodiesterase-IN-2
  • HY-161717
    MRS5663 1377272-66-6 98%
    MRS5663 (Compound 3a) is an A3AR agonist, with an EC50 of 5.62 nM for β-arrestin2 recruitment assay. MRS5663 has a cytoprotective effect on skeletal muscle ischemia-reperfusion injury/claudication model.
    MRS5663
  • HY-161730
    αvβ1 integrin-IN-3 98%
    αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect.
    αvβ1 integrin-IN-3
  • HY-161836
    α2AR agonist 1 98%
    α2AR agonist 1 (compound S6a), a new morpholine-containing pyrimidinone, acts as an agonist of α2-adrenoceptor. α2AR agonist 1 induces a concentration-dependent relaxation on aortic ring pre-contracted with Phenylephrine (HY-B0769; pEC50=6.81). α2AR agonist 1 increases NOx and NO levels in HUVECs.
    α2AR agonist 1
  • HY-16183A
    Echothiopate chloride 120087-68-5 98%
    Echothiophate (Echothiophate) chloride is a highly effective, long-lasting cholinesterase inhibitor employed as a miotic for managing glaucoma. Echothiopate chloride forms a covalent bond with the serine residue at the active site of cholinesterase through its phosphate group, rendering the enzyme permanently inactive and necessitating the synthesis of new enzymes by the cell. Given its irreversible binding to cholinesterase and the extremely slow rate of hydrolysis, the effects of echothiophate can persist for a week or longer. Echothiopate chloride is utilized as an ocular antihypertensive agent in the treatment of chronic glaucoma and, in certain cases, accommodative esotropia.
    Echothiopate chloride
  • HY-161909
    USP30-I-1 2511541-78-7 98%
    USP30-I-1 is a selective inhibitor of USP30 with an IC50 value of 94 nM. USP30-I-1 can be used in the research of diseases with impaired mitophagy by targeting USP30.
    USP30-I-1
  • HY-161941
    MeIm 2043947-71-1 98%
    MeIm (compound 7) is a high-affinity PCSK9 targeting peptide mimetic with cholesterol-lowering activity. MeIm increases cellular uptake of LDL (EC50=6.04 μM) by inhibiting the binding of PCSK9 to LDLR (IC50=11.2 μM). MeIm can be used in the study of cardiovascular diseases.
    MeIm
  • HY-162060
    YPX-C-05 2894823-79-9 98%
    YPX-C-05 is a hydroxamic acid-based HDAC inhibitor. YPX-C-05 exerts significant vasodilatory effects. YPX-C-05 exhibits inhibitory effects on HDACs and increases histone H4 acetylation in endothelial cells. YPX-C-05 can be used for hypertension research.
    YPX-C-05
  • HY-162125
    AT2 receptor ligand-1 98%
    AT2 receptor ligand-1(compound 14) is a potent angiotensin AT2 receptor ligand with the Ki 4.9 nM. AT2 receptor ligand-1 shows high stability in microsomes of the sulfonamide ligands.
    AT2 receptor ligand-1
  • HY-162167
    COX-1-IN-1 1369503-03-6 98%
    COX-1-IN-1 (compound 15a) is a selective inhibitor for cyclooxygenase (COX), with IC50s of 0.23 μM (COX-1) and >50 μM (COX-2), selective index (COX-2 IC50/COX-1 IC50) is 217. COX-1-IN-1 inhibits platelet aggregation.
    COX-1-IN-1
  • HY-162246
    Nav1.8-IN-5 3023247-79-9 98%
    Nav1.8-IN-5 (Example 1) is a voltage-gated sodium channel Nav1.8 inhibitor. Nav1.8-IN-5 can be used for Nav1.8-mediated diseases, such as pain and pain-related disorders, as well as cardiovascular diseases (such as atrial fibrillation) research.
    Nav1.8-IN-5
  • HY-162374
    ANO61 940476-20-0 98%
    ANO61 is a dibenzyl formamide derivative, which exhibits an antiplatelet efficacy through modulation of thrombin-induced Ca2+ response with an IC50 of 47.7 μM.
    ANO61
  • HY-162375
    AF299 832685-79-7 98%
    AF299 can reduce collagen-related peptide-induced platelet Ca2+ rises and collagen-induced platelet aggregation. AF299 can be used for research of antiplatelet research.
    AF299
  • HY-162401
    AZ7976 2813866-27-0 98%
    AZ7976 (Compound 42) is a highly selective agonist for the Relaxin Family Peptide Receptor 1 (RXFP1) (pEC50 > 10.5). AZ7976 enhances RXFP1's cAMP signaling through an allosteric mechanism, thereby physiologically increasing heart rate. AZ7976 can be used in the field of cardiovascular disease research.
    AZ7976
  • HY-162513
    DPP-4-IN-10 1123219-12-4 98%
    DPP-4-IN-10 (compound 1) is a DPP-4 inhibitor. DPP-4-IN-10 is orally active. DPP-4-IN-10 blocks the degradation of GLP-1 and GIP, which may improve glycemic control in type 2 diabetes (T2MD).
    DPP-4-IN-10
  • HY-162555
    BMS-986308 2254333-97-4 98%
    BMS-986308 is a selective and orally active renal outer medullary potassium (ROMK) channel inhibitor. BMS-986308 is selective for ROMK over hERG. BMS-986308 can be used for heart failure research.
    BMS-986308
  • HY-162609
    ST-2560 98%
    ST-2560 is a selective inhibitor of the NaV1.7 sodium channel with IC50 value of 39 nM. ST-2560 can be used to study pain behavior and cardiovascular models.
    ST-2560
  • HY-162646
    FXIIa-IN-5 3047411-80-0 98%
    FXIIa-IN-5 (Compound 4J) is an orally active, selective inhibitor for factor XIIa (FXIIa), with IC50 of 21 nM. FXIIa-IN-5 inhibits the intrinsic coagulation pathways, and exhibits anti-inflammatory and antithrombotic activity in Carrageenan (HY-125474)-induced mice thrombosis models. FXIIa-IN-5 exhibits moderate pharmacokinetic characteristics and slightly toxicity (at 100 mg/kg).
    FXIIa-IN-5
Cat. No. Product Name / Synonyms Application Reactivity